The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids

David C Warhurst*1, John C Craig2, Ipemida S Adagu1, David J Meyer1 and Sylvia Y Lee1

Address: 1Pathogen Molecular Biology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel St., London WC1E 7HT, UK and 2Department of Pharmaceutical Chemistry, University of California, San Francisco, California, CA 94143-00446 USA

Email: David C Warhurst* - david.warhurst@lshtm.ac.uk; John C Craig - david.warhurst@lshtm.ac.uk; Ipemida S Adagu - ipemida.adagu@lshtm.ac.uk; David J Meyer - david.meyer@lshtm.ac.uk; Sylvia Y Lee - sylviaylee@hotmail.com

* Corresponding author

Abstract

Background: The 8-amino and 9-hydroxy substituents of antimalarial cinchona alkaloids have the erythro orientation while their inactive 9-epimers are threo. From the X-ray structures a 90° difference in torsion angle between the N1-H1 and C9-O12 bonds in the two series is believed to be important. In order to kill the malaria parasite, alkaloids must cross the erythrocyte and parasite membranes to accumulate in the acid digestive vacuole where they prevent detoxication of haematin produced during haemoglobin breakdown.

Methods: Ionization constants, octanol/water distribution and haematin interaction are examined for eight alkaloids to explain the influence of small structural differences on activity.

Results: Erythro isomers have a high distribution ratio of 55:1 from plasma to the erythrocyte membrane, while for the more basic threo epimers this is only 4.5:1. This gives an increased transfer rate of the erythro drugs into the erythrocyte and thence into the parasite vacuole where their favourable conformation allows interaction with haematin, inhibiting its dimerization strongly (90 ± 7%) and thereby killing the parasite. The threo compounds not only enter more slowly but are then severely restricted from binding to haematin by the gauche alignment of their N1-H1 and C9-O12 bonds. Confirmatory molecular models allowed measurement of angles and bond lengths and computation of the electronic spectrum of a quinine-haematin complex.

Conclusion: Differences in the antiplasmodial activity of the erythro and threo cinchona alkaloids may therefore be attributed to the cumulative effects of lipid/aqueous distribution ratio and drug-haematin interaction. Possible insights into the mechanism of chloroquine-resistance are discussed.

Background

Aryl amino alcohol alkaloids from the bark of Cinchona spp. have played an invaluable role in the treatment of malaria since the 18th century when the extract became widely used. The bark contains laevorotatory (-) quinine (6'-methoxy cinchonan-9-ol) (Q), its diastereomer dextrorotatory (+) quinidine (QD), and their 9-epimers epiquinine (EQ) and epiquinidine (EQD). Also present are (−) cinchonidine (des methoxyquinine) (CD), its diastereomer (+) cinchonine (C) and their 9-epimers...
epicinchonine (EC). With the purification of Q as the major alkaloid, it remains the main therapeutic drug for severe and complicated *Plasmodium falciparum* malaria [1]. In addition to the above alkaloids, all of which contain the exocyclic unsaturated vinyl group attached to C3 of the quinuclidine ring, *Cinchona* bark produces the analogous dihydro compounds of which hydroquinine (HQ) and its diastereomer hydroquinidine (HQD) are examples, in which the exocyclic double-bond has been reduced to the saturated ethyl group (figure 1).

Q and other aryl amino alcohols competitively inhibit [2] morphological changes caused by chloroquine (CQ) [3,6] in digestive vacuoles (lysosomes) of the erythrocytic parasite where haemoglobin is digested. All these agents become concentrated in infected erythrocytes [4], and, as weak membrane-soluble bases, are believed to accumulate in the acidic digestive vacuole contents where they undergo protonation [5]. They are thought to cause the death of the intraerythrocytic malaria parasite by binding to toxic haematin [6,7] released during haemoglobin digestion, preventing its dimerization to non-toxic malaria pigment (haemozoin, β-haematin [8]).

In chemical structure, cinchona alkaloids consist of a conjugated heterocyclic quinoline ring, joined to a bulky rigid bicyclo heterocyclic aliphatic quinuclidine ring by an alcoholic carbon, C9. This is one of four chiral centres in these molecules; only C8 and C9 vary in configuration, while C3 and C4 on the aliphatic ring (respectively rectus, R and sinister, S), are *erythro* and invariant. Centres C8
and C9 are S and R in Q and R and S in QD, both erythro. Their 9-epimers are 8S and 9S in EQ and 8R and 9R in EQD, both threo. (figure 1) In 1938 it was reported from the Wellcome Laboratories of Tropical Medicine, London, that EQ and EQD had little activity against experimental avian malaria [9]. Further, a clinical study found in 1948 that while Q and QD effectively treated induced P. falciparum infections, QD was twice as potent as Q as P [10]. Unnatural (8R,9S,3S,4R) HQ and (8S,9R,3S,4R) HQD synthesized at Hoffmann La Roche by Brossi’s group were each as active in P. berghei infections in mice as natural HQ and HQD [24].

Before P. falciparum cultures [11] were available, EQ was confirmed inactive in short-term cultures of P. berghei. In agreement with the earlier clinical study, QD was four times more active than Q, and C three times more active than CD, emphasising the antiparasitic superiority of the dextrorotatory (+) alkaloids of the QD type [2].

In the synthetic aryl amino alcohols, however, erythro (1SR, 2RS)-mefloquine (WR 142,490) was only 2.5 times more active than the threo (1RS, 2RS)- racemate WR 177,602, and erythro WR 122,455 was 0.7 times as active as its threo racemate WR 165,355. This small difference in relative activities of erythro and threo mefloquine and WR 122,455, compared with the lack of activity of the threo epimers of the cinchona alkaloids, was attributed to the ease of rotation of the less bulky piperidine ring, which replaces the quinuclidine ring in these synthetic agents, around the link between the two relevant asymmetric carbon atoms (C-8 and C-9 in the cinchona alkaloids). As a result of these studies a drug receptor was proposed, comprising 2 planar areas accommodating the quinoline rings of Q and QD with, in between, an electropositive area in the plane and a raised electronegative area [2]. The receptor concept was refined in 1981 on the basis of an experimental study of haematin interactions with aryl amino antimalarial drugs, and evidence for a co-ordination link between such drugs and haematin iron was obtained [12].

In 1990, using cultures of CQ-sensitive P. falciparum, Wesche & Black confirmed higher activity of (+)QD than (-) Q, and of (+) C than (-) CD [13]. In addition, Karle et al. [14] found that, like (+) QD vs. (-) Q, (+) mefloquine was slightly more effective than (-) mefloquine against P. falciparum in vitro but this difference did not apply to enantiomers of aryl amino alcohols whose side-chains were more flexible than piperidine. They found in a further study that EQ and EQD were approximately 100 times less active than quinine and quinidine against chloroquine-sensitive P. falciparum in vitro while HQ and HQD were about 25% more active than Q and QD against CQ-sensitive P. falciparum in vitro [15].

One explanation for the much lower activity of EQ and EQD had been the suggested potential for intramolecular H-bonding between aliphatic N-1 and adjacent O-12 because of the shorter distance between these atoms [16], thereby reducing the ability of the drug to interact with a putative cellular receptor site. Crystallographic evaluation by Karle et al. revealed that the N-1 to O-12 distances in the epimers were similar to those of other active amino-alcohol antimalarials, and all showed potential for forming H-bonds with cellular constituents. However, the torsion angle between the N1-H1 and C9-O12 bonds showed a 90° difference between the erythro- and threo-alkaloids. These authors concluded that the main reason for the inactivity of EQ and EQD was that threo-alkaloids could not form intermolecular H-bonds with cellular receptor sites in the same direction as the active erythro-isomers [15]. Recently Karle & Karle have compared the crystal structures of Q and QD with those of (-) and (+) mefloquine to derive a pharmacophore which defines the main features of the parasite’s receptor [17].

Their findings are of considerable interest with respect to the proposed receptor for these drugs, haematin, which has a large planar area containing 4 N atoms co-ordinated with FeIII. The Q-haematin complex is formed by hydrophobic interaction between the conjugated rings and co-ordination between FeIII and the hydroxyl group on C-9 of Q [18]. In water, solid haemin chloride (monomeric haematin) will readily dissolve in solutions of the antimalarial active erythro alkaloids Q, QD, CD and C to form benzene-soluble co-ordination complexes with α- and β-hemichrome absorption peaks around 600 and 490 nm. This does not occur with the inactive EQ [12]. More recently, it has been shown that Q, but not EQ, inhibits spontaneous haematin dimerization to β-haematin in vitro [19].

We report below that haematin dimerization is also not inhibited by EQD and confirm the lack of activity of EQ and the activity of Q, QD, HQ, HQD, C and CD in this model system. We have also obtained reliable values for the octanol/water partition coefficients (Log P) and ionization constants (pKₐ values) of Q, QD, HQ, HQD, EQ, EQD, C and CD. This enables us to predict the log distribution ratio between water and lipid (logD) both at the physiological pH and at the acidic pH of the parasite lysosome, where haematin is released from haemoglobin, and to calculate the possible intralysosomal concentration ratios that would be expected, assuming the drugs are concentrated by hydrogen ion. These observations are discussed in the context of molecular modelling, in order to evaluate physicochemical and structural determinants of drug activity against chloroquine-sensitive and resistant P. falciparum. Our conclusions throw light on the prerequisites for activity in cinchona alkaloids, the nature of the
haematin-quinine interaction, and the mechanism of chloroquine-resistance.

**Methods**

**Physicochemical data**

The accumulation of an ionizable drug in cells is determined (apart from special transport mechanisms) by two major parameters: the partition coefficient $P$ between the aqueous and the lipid phase, usually expressed as log $P$ (measured in the octanol-water system for the un-ionized compound), and its modification by the ionization constant(s) (pKa) of the drug. For partially ionized compounds, the partition coefficient between 2 phases at any fixed pH is called the distribution coefficient $D$, usually expressed as log $D$; this assumes that only the un-ionized species partitions from the aqueous to the organic phase [20]. The difference between log $P$ and log $D$ is, therefore, determined by the percentage of the drug ionized at different pH values and is given by the standard equation for a base [21]. When the difference between pKa and pH is more than 1.0 log unit, it has been shown [22] that one can merely subtract this difference from log $P$ to obtain log $D$. This makes it possible to calculate log $D$ [23] from a knowledge of log $P$, pKa, and pH. The availability of the ClogP programme, developed by C. Hansch and A. Leo at Pomona College, California, as part of the Pomona College Medicinal Chemistry Project, has now provided a useful method of computing approximate log $P$ values for compounds of known structure. Values may sometimes be unreliable since differences due to conformational isomerism are not detected [25].

In the case of a drug possessing two basic centres, as quinoline antimalarial drugs all do, the correction needed in log $P$ to obtain log $D$ at a given pH involves the additive contribution of both ionized species, and the base equation [21] must be modified: [26,28].

**Equation (1)** for a diacidic base

\[
\log D = \log P - \log[1 + 10^{(pK_{a1} - pH)} + 10^{(pK_{a1} + pK_{a2} - 2pH)}]
\]

Log $D$ at the physiological pH of 7.4 was obtained experimentally from the plot of log $D$ versus pH. This was compared with the calculated value of Log $D$, obtained from Log $P$, using equation (1). Log $D$ at the probable pH of the digestive vacuole or lysosome was calculated from log $P$ by substituting pH 5.2 [27] for 7.4 in equation (1). The application of equation (1) provides a useful rapid method of checking measured values of log $D$, and of calculating these values from log $P$ when unknown. It should be noted that for diacidic bases, $pK_{a1} > pK_{a2}$.

**Vacuolar accumulation ratios**

To calculate the vacuolar accumulation ratios (VAR) that weakly basic lipophilic drugs might achieve by virtue of the pH difference between lysosome and external medium or plasma [5], the equation of Henderson & HasSELbach was used in the following form [29].

**Equation 2**

\[
[Drug_{vac}]/[Drug_{outside}] = 1 + 10^{pK_{a1} - pH} + 10^{pK_{a1} + pK_{a2} - 2pH}
\]

Dissociation constants and partition coefficients were determined by Robertson Microlit Laboratories (Madison, New Jersey, USA) at 25°C using the Sirius GLpK automated computerized potentiometric system [30]. Titration employed water containing 0.15 N KCl in an argon atmosphere. The pKa's were determined in triplicate with a S.E. of ±0.20.

Partition coefficients between octanol-1-ol and water were measured by dual-phase potentiometric titration using various amounts of water-saturated octanol. Titrant addition was carried out with vigorous stirring of the assay solution. Three different ratios of octanol/water were employed for each compound. The log $P$ values were obtained from the difference between the aqueous pKa of the species and the apparent pKa determined from the dual phase titration [31]. Measurements were carried out in triplicate with a S.E. of ± 0.40. The potentiometric method was validated by comparison with results obtained by the standard shake-flask technique [32].

The drug lipophilicity values at pH 7.4 and 5.2 (log $D$) are the octanol/water distribution ratios, and were obtained from the plot of log $P$ versus pH. Calculated log $D$ values for pH 5.2, representing the conditions in the lysosome, and for log $D$ at pH 7.4, were obtained using equation (1).

**β-Haematin Inhibitory Activity: BHIA**

The method was slightly modified from Parapini et al. [33]. The 8 M sodium acetate/acetic acid buffer (pH 5.0) was prepared as follows:

Make up solid sodium acetate to 8 M with warm water (continue to heat at 37°C in a water bath while mixing: it will not dissolve completely) and then adjust the pH to 5.0 with 8 M acetic acid at 37°C, which leads to the remaining solid dissolving).

One hundred µL was dispensed into wells of a microtitre plate, and 50 µL of alkaloid hydrochloride or sulphate solution in water, at 80 mM, or water alone, was added. Verapamil (VE) and promethazine (PMZ) (Sigma Chemicals, Poole, UK) were used as hydrochlorides. CQ (Sigma, UK) was used as the diphosphate. Addition of 50 µL of an
8 mM α-chlorohemin (Sigma, UK) solution in DMSO to each well started the experiment.

Experiments were allowed to run at 35°C for 24 hr., done in triplicate and repeated on three occasions. The final DMSO concentration in this system was 25% w/v, while final haematin concentration (0.4 µmol/well) was 2 mM, and the final drug concentration (4.0 µmol/well) was 20 mM. Drug/haematin molar ratio was 10:1.

Then insoluble β-haematin and haematin aggregate were pelleted by centrifugation at 3000 g for 20 min at room temperature (22°C) and the supernatant discarded. Two hundred µL of DMSO were added to each pellet to dissolve un-reacted haematin and centrifugation was repeated. After discarding the supernatant, 200 µL of 0.2 M NaOH were added to convert the β-haematin pellet to soluble alkaline haematin. For each well the alkaline haematin was quantified by serial twofold dilution in water and OD measurement at 414 nm. The effect of each agent on β-haematin production was recorded compared with the control (water + DMSO + acetate buffer alone).

### Molecular Modelling

Each mono-protonated cinchona alkaloid structure was built in HyperChem Release 7 for Windows (Hypercube Inc. Gainesville, Florida) using a molecular mechanics procedure under MM+ [34] with bond-length restraints for N1-O12 and N1 to C5’ distance [15] (bond dipoles, no cut offs employed). The geometry was optimised to an rms (root mean square) gradient of 0.001 in vacuo (Polak-Ribière method). A periodic box, 15 × 15 × 15Å around the drug was then set up, containing 112 water molecules. The system was optimised in MM+ using switched cut-offs (outer 7.5 and inner 3.5 Å), to an rms gradient of 0.5. Then a molecular dynamics programme was run for 1 ps, with 0.001 ps steps, relaxation time 0.1 ps, to a simulation temperature of 300 K. This was followed by MM+ geometry optimisation to an rms gradient of 0.2. The molecular dynamics run was repeated and a further MM+ protocol was carried out to a gradient of rms 0.004 on the selected drug.

Angles and bond-lengths were measured on the models, and the dipole moments were determined after removal of the N-1 proton, using the semi-empirical PM3 programme [35,36] in singly-excited configuration interac-

---

Table 1: Physicochemical parameters of Cinchona alkaloids. cpd. = compound, VAR = calculated vacuolar accumulation ratio. S = chloroquine-sensitive, R = chloroquine-resistant. S/R = ratio of IC50 values. BHIA = % inhibition in β-haematin inhibition test

| Cpd. | pK a1 | pK a2 | Log P | Log D (pH7.4) | Log D (pH5.2) | VAR | IC50 nM S | IC50 nM R | RATIO S/R | BHIA % inhib. |
|------|-------|-------|-------|--------------|--------------|-----|-----------|-----------|-----------|----------------|
| Q    | 8.58a | 4.12b | 3.17c | 1.97e        | 0.30         | 161.0 | 29.315   | 103.215   | 0.28      | 84 ± 1         |
| QD   | 8.58g | 4.42h | 2.84i | 1.66j        | 0.40k        | 173.2 | 13.415   | 43.715    | 0.31      | 85 ± 9         |
| HQ   | 9.01i | 4.29  | 3.07j | 1.50k        | 0.53         | 173.6 | 21.315   | 151.715   | 0.14      | 93 ± 0.6       |
| HQD  | 9.16  | 4.34  | 3.43l | 1.72m        | 0.75         | 177.5 | 10.414   | 74.114    | 0.14      | 95 ± 0.4       |
| C    | 8.35m | 4.28n | 2.82o | 1.85p        | -0.38r       | 159.6 | 18.346   | 70.846    | 0.26      | 94 ± 0.5       |
| CD   | 8.40q | 4.17r | 2.68s | 1.73t        | -0.56u       | 157.5 | 69.546   | 206.846   | 0.34      | 94 ± 0.4       |
| EQ   | 9.54u | 4.08  | 2.90v | 0.76w        | -1.44x       | 169.2 | 347.115  | 117.915   | 2.94      | 2 ± 13         |
| EQD  | 9.39v | 4.15  | 2.53w | 0.55x        | -1.2         | 170.8 | 2700.15  | 1024.15   | 2.64      | 12 ± 12        |
| CQ   | 10.18 | 8.38  | 4.72z | 0.92f        | -3.44g       | 22750 | 18.5     | 264.07    | 0.07      | 81 ± 15        |
| VE   | 8.42  | <0    | 3.79  | 2.75f        | 0.59h        | 144.2 | 720053   | 250053    | 2.88      | 0 ± 21         |
| PMZ  | 9.14  | <0    | 4.75  | 3.03f        | 0.84g        | 155.5 | 143652   | 83552     | 1.70      | 15 ± 22.5      |

- a: Lit. 8.43[64], 8.4[39], 8.05[65], 8.59[66]. In 80% methylcellosolve/20% water 7.73[41], 7.25[67]; b: Lit. 4.34[64], 4.32[39], 4.33[66]. In 80% methylcellosolve 2.81[67], 2.38[68]; c: Lit. 3.44[22], 2.64[65]; d: Calc. from CLogP; e: Lit. 1.90[65], 2.14[22], 2.54[69], 1.73(pH7.0)[70]; f: Calc from eqn. (1). ; g: Lit. 8.79[64], 7.95[41], 8.78[42]. In 80% methylcellosolve 7.95[41]7.36[67]; h: Lit. 4.34[64], in 80% methylcellosolve 2.66[67], 2.40[68]; i: Lit. 2.88[65], 3.71[42]; j: Lit. 2.03[72], 2.07[74], 2.11[31], 2.22[65]; k: Lit.-0.07[42]; l: Lit. 8.87[40]; m: Lit. 8.35[40], 8.32[65]. In 80% methylcellosolve 7.36[68]; n: Lit. 4.28[67]. In 80% methylcellosolve 2.80[67], 2.15[68]; o: Lit. 2.82[65]; p: Lit. 1.85[65]; q: Lit. 8.40[40], 8.30[65]; r: Lit. 4.17[40]. In 80% methylcellosolve 2.66[67], 2.12[68]; s: Lit. 2.68[65]; t: Lit. 1.73[65]; u: Lit. In 80% methylcellosolve 8.44[41]; v: Lit. in 80% methylcellosolve 8.32[41].
tion. (RHF [Restricted Hartree-Fock], charge 0, spin multiplicity 1, lowest state, orbital criterion, five occupied and five unoccupied orbitals.)

Models of the Q-haematin and EQ-haematin complexes were prepared in MM+ using the structures of Q and EQ optimised in water (see above), with a co-ordination link between haematin iron and drug O-12. The crystal structure of α-chlorohaemin [37] was used for the initial haematin monomer model.

The semi-empirical quantum mechanics program ZINDO/S [38] in singly excited configuration interaction was used to calculate the expected electronic spectrum of the optimised 1:1 quinine/haematin complex in benzene. One molecule of singly protonated quinine, coordinated to one molecule of haematin, with carboxylic acid groups undissociated, was given an arbitrary charge of +1 and spin multiplicity of four. Fifteen occupied and 15 unoccupied orbitals were included in the calculation.

(EQ and EQD were kindly supplied by Dr. Reinecke of Buchler GmbH, D-38110 Braunschweig, Germany.)

Results

Physicochemical

Q and QD, C and CD are reported to have very similar pK_{a1} values (8.4 ± 0.4) for the quinuclidine aliphatic N (table 1: footnotes). A value of 8.5 ± 0.15 (table 1) was found, with a slight increase in HQ and HQD due to the conversion of the electron-attracting vinyl group to an ethyl group. All the cinchona alkaloids in table 1 had very similar pK_{a2} values (4.25 ± 0.15) for the more weakly basic quinoline aromatic N. The only previous determinations [41] for the three compounds EQ and EQD were carried out in 80% methyl-cellosolve/20% water and showed both 9-epimers to have higher pK_{a} values than Q and QD in the same solvent. Results obtained in water (Table 1) confirmed this finding and revealed a consistent ΔpK_{a} of 1.1 units between the two solvent systems, and of 1pK_{a} unit between the erythro and the three isomers. Experimental values for log P are shown in table 1 as are the figures calculated using the ClogP programme. The two sets are in generally good agreement, and show the expected slight increase (+0.4) with the dihydro compounds (HQ and HQD) and decrease (-0.3) with the loss of the 6-methoxy group (C, CD). Experimental measurement of log D vs pH over the range 3–11 permitted the determination of log D at pH 7.4. In addition knowledge of log P and pK_{a} allowed the calculation of log D at pH 7.4 using equation (1). Measured and calculated figures (table 1) are in good agreement, while reported values (table 1: footnotes) show a wider variation. Results for log D at pH 7.4 for the erythro compounds fall in the range 1.50–1.97 (mean 1.74 ± 0.24) while the three isomers (range 0.55–0.76) show a mean of 0.66 ± 0.11. In view of the acidic milieu (pH 5.2) existing in the vacuole within the lysosomal membrane, log D at pH 5.2 was also measured and calculated and the figures are shown in table 1. The comparison of calculated results for these agents at pH 5.2 with those obtained for chloroquine (CQ) is of interest, since because of CQ’s two high pK_{a} values [43,44], the drop in pH had a much larger influence than on Q, QD, EQ or EQD. The drop in log D between pH 7.4 and pH 5.2 for Q, QD, EQ and EQD was ~2 logs while for CQ it was > 4 logs.

The parasite lysosome, which has been proposed as the main site of drug uptake, has an acidic pH. Assuming drug distribution reaches an equilibrium state, and only uncharged drug can pass through membranes, it is argued that the ratio between concentration of drug outside the erythrocyte and the concentration in the lysosome depends on the difference between [H+] of the medium in vitro or plasma in vivo (pH 7.4), and the lysosomal compartment, according to the Henderson-Hasselbach equation [5]. Both the water/lipid partition (log P) and the acid dissociation constant(s) (pK_{a}) of a drug influence the passage of drug into the lysosome and its trapping by protonation. Trapping of a drug in the acidic vacuole is enhanced if the base, like chloroquine (CQ), can accept more than one proton at the lysosomal pH [28]. Calculated CQ concentrations within the infected erythrocyte approximate to measured uptake values, but the more lipophilic agents like amodiaquine (AQ) achieve significantly greater levels than calculated, indicating that other factors are involved in the concentrative uptake of the drug [29]. Calculated lysosomal uptake ratios (vacuolar accumulation ratio: VAR, the ratio of calculated drug concentration in the lysosomal water to concentration in the external medium at equilibrium) for cinchona alkaloids, for resistance-reversers VE and PMZ, and for CQ are given in table 1. The most interesting finding here was the small variation in calculated VAR seen among the eight alkaloids examined (mean: 167.8 ± 7.4 [SD]). The minor variation reflects slight differences in the protonation of the aromatic N at pH 5.2, while the aliphatic N is 100% protonated in all the alkaloids examined.

BHIA test

A 10 fold molar excess of Q, QD, HQ, HQD, C, CD, or CQ inhibited the BHIA haematin dimerization reaction. Significant inhibition was not seen with EQ, EQD, VE or PMZ. (Table 1, figure 2). These results fit in with the reported high activity of CQ [73] and the erythro cinchona alkaloids on P. falciparum and the low activity of EQ, EQD [15,46], PMZ [52] and VE [53].
Molecular modelling (table 2)

As pointed out by Karle and co-workers, [15,46], the N1-H1 bond in 8, 9 *threo*-alkaloids consistently points in the same direction as the C9-O12 bond, while in the *erythro*-alkaloids they are at right angles (see the last column of table 2). The calculated dipole moment and proton affinity of each active alkaloid are lower than that of its 9-epimer, as first demonstrated by Karle & Bhattacharjee [46]. This is confirmed by our finding of higher pK$_a$ values for the 9-epimers (table 1). Dipole moments and proton affinities calculated here consistently differ from values in ref. [46], probably because we used a semi-empirical configuration interaction calculation rather than an *ab initio* approach.

Space-filling models of the cinchona alkaloids orientated to face a putative receptor are shown in figure 3.

Q-haematin model

A Q-haematin co-ordinated model was calculated using MM+, in comparison with EQ-haematin. The results of the ZINDO/S calculation of the electronic absorption spectrum of Q-haematin are compared with experimental observations in table 3 below. Differences in the orientation of the N1 proton with respect to the quinoline and porphyrin rings are shown in figure 4 below.

Discussion

The cinchona alkaloids have an aromatic N with a pK$_a$ of 4.25 ± 0.15. At pH 7.4 the aromatic N is 100% un-ionized and makes its maximum contribution to lipophilicity. In the active *erythro* alkaloids, with partial protonation of the aliphatic N, this results in a log D at pH 7.4 of 1.74 ± 0.25 corresponding to a favourable mean membrane transfer ratio into the lipid phase of 55:1. This is applicable to the

---

Figure 2
% β-haematin synthesis inhibition (BHIA) by cinchona alkaloids, chloroquine (CQ), verapamil (VE), promethazine (PMZ) and water (Cont). Standard deviations are shown (n = 9).
Table 2: Electronic and structural parameters of cinchona alkaloids in aqueous solvent, based on the common pharmacophores described for (-) mefloquine and quinine and (+) mefloquine and quinidine by Karle & Karle [17]. (*dipole moment calculated for free base).

| drug   | MM+ energy in water | dipole moment* | proton affinity | O12-N1 torsion° | N1-C5° ring-O12 torsion° | O12-N1 torsion° | H8-C9-H9 dihedral° | H-N1-C9-O12 torsion° |
|--------|---------------------|----------------|-----------------|-----------------|------------------------|-----------------|---------------------|---------------------|
| Q      | 11.9                | 1.88           | 208.85          | 3.14            | 4.1                    | 157.8           | -83.8               | -123.2              |
| EQ     | 15.5                | 2.44           | 213.36          | 2.77            | 4.7                    | 40.6            | 43.3                | 174.0               | -5.9                |
| QD     | 18.9                | 1.66           | 208.61          | 3.09            | 4.2                    | -161.1          | 78.2                | 74.7                | 104.4               |
| EQD    | 12.8                | 2.21           | 213.84          | 2.82            | 4.7                    | -43.2           | -49.1               | -175.8              | 0.6                 |
| CD     | 11.1                | 1.15           | 209.38          | 3.21            | 4.2                    | 144.9           | -91.0               | -86.8               | -129.6              |
| ECD    | 13.6                | 1.54           | 213.88          | 2.79            | 4.6                    | 45.1            | 46.0                | 175.0               | -5.9                |
| C      | 10.9                | 0.96           | 209.78          | 3.19            | 4.1                    | -156.0          | 88.9                | 85.3                | 118.3               |
| EC     | 13.5                | 1.27           | 213.75          | 2.85            | 4.7                    | -45.4           | -50.2               | -176.2              | -2.5                |
| HQ     | 10.4                | 2.08           | 209.39          | 3.20            | 4.1                    | 156.1           | -83.6               | -82.8               | -123.6              |
| HQD    | 10.7                | 1.79           | 209.75          | 3.23            | 4.2                    | -152.7          | 89.5                | 88.8                | 118.6               |

Figure 3
Space-filling models of cinchona alkaloids optimised in solvent water. Each structure is orientated facing a putative receptor. N = dark blue, C = light blue, O = red, H = grey.
transfer of drug from blood plasma water to erythrocyte and subsequent membranes. For the (weakly active) threo epimers, the higher pKₐ of the aliphatic N, which is now 100% ionized and does not contribute to transfer into the lipid phase, reduces log D at pH 7.4 by one magnitude to 0.66 ± 0.1, corresponding to a decreased membrane transfer ratio of only 4.5: 1. It is known that CQ and other 4-aminoquinoline antimalarials need to reach a high concentration within the lysosome of the CQ-sensitive parasite in order to inhibit dimerization of the enclosed haematin [47], and this is also assumed to apply to cinchona alkaloids. The rise in pKₐ values observed for the inactive 9-epi alkaloids will therefore lower the rate at which that effective concentration is reached. The acidic

| α peak (nm) | β peak (nm) | γ peak (nm) | α peak × strength | β peak × strength | γ peak × strength | [Q] / [H] |
|-------------|-------------|-------------|------------------|------------------|------------------|----------|
| observed    | 602         | 490         | 408              | 10               | 1.2              | 1        | 0.8     |
| calculated  | 545.4       | 489.4       | 408.4            | 5.4              | 1.1              | 1        | 1       |
| Ratio obs/calc | 1.1       | 1.0         | 1.0              | 1.9              | 1.1              | 1        | 0.8     |

**Figure 4**
Views of Q-haematin and EQ-haematin models from the edge of the porphyrin ring to show comparative orientation (black arrows) of the electric field of the alkaloid N-1 proton (H-1). The haematin iron atom (just visible) is coloured magenta.
environment of the vacuole (pH 5.2) results in substantial ionization (~40%) of the aromatic N of the cinchona alkaloids, with enhanced water solubility as shown by the marked drop in log D (table 1), so that all eight compounds are trapped there, causing their concentration to increase in the low pH milieu.

The absence of significant inhibition of β-haematin formation by both 9-epi alkaloids tested strengthens the link between 8, 9 erythro configuration in cinchona alkaloids and antiplasmodial activity, and indicates that reaching a high concentration in the lysosome, though necessary, is not sufficient in itself to confer antiplasmodial activity. Once a drug is in the lysosome, it must be able to interact with haematin, or with other vital functions like the proteolysis of haemoglobin [48], in order to exert a toxic effect.

Reported molecular electronic properties [46] of Q and QD and their epimers are in agreement with measured pK_a values here. In Q and QD the positive electric field of the aliphatic N1 proton is directed towards the quinoline ring, and the dipole moment of the drug (unprotonated) is reported as 2.2 Debye or less, while in the 9-epimers EQ and EQD the field is directed towards the solvent and the dipole moment is higher. N1 in the erythro-alkaloids is in a position to interact with equatorial protons of the quinoline ring (C5' is only ~4 Å away). In the models the bulky quinuclidine group finds difficulty in rotating close to the quinoline ring in the three-alkaloids; the O-12 is interposed, and the N1-C5' distance is up to 4.7 Å (table 2), see also [15,46]. The probable reason for the higher proton affinity of the N1 and lower logD in the three alkaloids is that the quinoline ring has less influence on N1 because of these steric factors, which lead to higher values of pK_a (easier protonation) of N-1. This will also enhance interaction (H-bonding) with solvent water in the three compounds.

**The Q-haematin complex**

Some features of the modelled drug-haematin complexes are of interest. The Fe-O12 bond length is 1.846 Å in Q-haematin and 1.842 Å in EQ-haematin which can be compared with 1.847 Å for the O-Fe distance in the high-spin co-ordination complex with a phenoxide [49]. The minimum distance between the carbon atoms of the quinoline ring in the drug, and those in the porphyrin ring was 3.1 Å in both models. This would allow Van der Waals interactions between the conjugated rings for both Q-haematin and EQ-haematin.

The H1-Fe distance in Q-haematin is 4.6 Å, while in EQ-haematin it is 3.9 Å. Proximity of positive charges of N1 proton and iron in EQ-haematin, and the higher value of the proton charge [46] might make co-ordination complex formation more difficult than for Q-haematin. The more solvated, more positive, epimer N-1 proton may interfere with the initial hydrophobic interactions of the quinoline and porphyrin rings, affecting co-ordination of O-12 to haematin iron. The importance of solvent water interaction with protonated N1 in inhibiting hydrophobic binding to haematin is suggested by the observation that in 40% DMSO both Q and EQ interact similarly with haematin [50]. The direction of the positive electric field of protonated N1 determines the higher pK_a and solvent interaction and is likely to be, as suggested by Karle and colleagues [15,48], the crucial difference between the inactive and active cinchona alkaloids, since this difference in direction, shown in figure 4, alters both the stereochemistry of interactions between Q or EQ and haematin and increases the solvation and charge of N1-H1 in EQ. These considerations are supported by the lesser effect of the three/erythro distinction on the activity of mefloquine congeners and phenanthrene methanols (WR 122,455) where the piperidine ring is more easily able to rotate close to the quinoline ring.

The peak wavelengths and strengths of the calculated electronic absorption spectrum compare well with the observed spectrum of the aqueous complex, extracted into benzene, reported earlier [12] (table 3). Despite the fact that, in view of the discrepancy in wavelength and strength of the α-peak, the structure is not yet completely correct, the α- and β-peaks support the formation of a hydrophobic quinine-haematin co-ordination complex while the strong γ-peak at 408 nm indicates haematin iron in a high-spin state, as expected from the putative structure. This is similar to α-chlorohemin [37], where Fe^{III} is 0.45 Å above the plane of the porphyrin ring. It appears unlikely that the quinoline ring interacts with the other side of the haematin ring structure, as has been proposed for the quinoline ring of CQ [63] since a high spin co-ordination complex could not then be formed.

In summary, positive correlations between antimalarial activity and drug lipophilicity have been reported [43,45,47] for a number of 4-aminoquinoline drugs related to CQ and amodiaquine (although not for the cinchona alkaloids) as well as for some aminothiol [74] and hydroxamate [75] chelators. In addition, a proportionality between activity and inhibition of formation of β-haematin has been recognized for 4-aminoquinolines [76] and also for Q and QD [19]. The present report, however, suggests that the differences in the antiplasmodial potency of the erythro and three cinchona alkaloids on CQ-sensitive isolates of *P. falciparum* may be accounted for as the cumulative consequences of their log D (pH 7.4) and BHIA values. The availability of these two critical parameters within this highly homogeneous group of drugs (table 1) makes it possible to apply a simple test.
of their sequential and combined effects: The ratio of the mean log D (pH 7.4) for the \textit{erythro} compounds (1.74 ± 0.24) to that of the \textit{threo} compounds (0.66 ± 0.11) is 12:1. The BHIA values for the 2 series are 90 ± 7% and 7 ± 4%, with a similar ratio of 12.5:1. Since these effects are cumulative, their combined result would raise the mean IC50 value for the \textit{threo} series to 150 (ie 12 × 12.5) times that of the \textit{erythro} group. With an experimental mean IC50 of the \textit{erythro} alkaloids of 26.7 nM, the calculated reduction of activity of the \textit{threo} alkaloids leads to an expected mean IC50 of (26.7 × 150) ie 4.0 \textmu M, while the observed experimental value is 3.1 ± 0.4 \textmu M. Alternatively the enhancement in activity of the \textit{erythro} series would lead to an IC50 of 3085/150 ie 20.6 nM; the experimental mean for the 6 \textit{erythro} compounds is 26.7 nM.

The agreement between the calculated and experimental values of IC50 is noteworthy.

These observations may provide a useful platform for the further investigation of antimalarial agents, particularly in the climate of increased drug-resistance.

\textbf{Lessons for the interpretation of CQ-resistance mechanisms}

Our arguments so far have concentrated on the probable role of hydrophobicity (logD) and inhibition of haematin dimerization as the determinants of antimalarial activity among eight cinchona alkaloids. Clearly these factors are also important in activity against CQ-resistant isolates. However, a further parameter, interaction with the CQ-resistance mechanism, must also be considered. Entry to the cell, concentration in the acidic lysosomal vacuole,

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure5.png}
\caption{LogD and activity in CQ-resistance: 4-aminoquinolines and cinchona alkaloids}
\end{figure}

\textbf{Figure 5}

LogD values at pH 7.4 and activity in CQ-resistance (log [IC50\textsubscript{S}/IC50\textsubscript{R}]) for 4-aminoquinolines and cinchona alkaloids. 4-aminoquinoline values from ref. [73].
and interaction with haematin have all been postulated as the site of the resistance mechanism. Arguments [61,77,78] and evidence [51,79,85] for and against drug efflux have not yet reached a consensus. Nevertheless, the most important mutations associated with CQ-resistance are in the genes coding for two intrinsic proteins in the membrane of the lysosome [80,56] where quinoline drugs are believed to be concentrated.

One of these, PGH-1, is a protein of the multidrug-resistance type [81], where over-expression is associated with resistance to highly hydrophobic drugs such as mefloquine, halofantrine and artemisinin [82–84]. The other, is PfCRT, where a Lys76Thr mutation is 100% associated with CQ-resistance in vitro [56]. In clinical studies, inability to detect the mutant allele predicts treatment success with CQ, halofantrine and artemisinin [82–84]. The other, is the PfCRT channel and their positive charge would prevent 4-aminoquinoline to the channel. The high hydrophobicity in acid of VE and PMZ (see table 1) would allow them to bind in a mutated PfCRT, since the high drug pressure for efflux, given a suitable channel. For 4-aminoquinolines, the positive correlation between hydrophobicity and relative activity in CQ-resistant isolates, like VE and PM [52,53]. We are investigating a link between polymorphism in PfCRT, resistance reversal by VE, and the clinical efficacy of AQ (in press).

VE and PM show no significant interaction with the haematin polymerisation process (table 1, figure 2) and they have little intrinsic antiplasmodial action. Combining our recent data on 4-aminoquinolines [73] and the erythro cinchona alkaloids studied here there is a significant correlation between hydrophobicity and log relative activity in CQ-resistant parasites, extending the observations of Bray et al. [54] (figure 5).

It has been proposed [61,73] that 4-aminoquinolines which are more polar at lysosomal pH (such as CQ) are more likely to pass through the mutated PfCRT channel and escape from the lysosome into the parasite cytoplasm, while those which are more hydrophobic (AQ and its active metabolite DAQ) are likely to bind to the hydrophobic channel lining and stay inside. Their positive charges repel the further access of 4-aminoquinoline to the channel. The high hydrophobicity in acid of VE and PMZ (see table 1) would allow them to bind in a mutated PfCRT channel and their positive charge would prevent efflux of CQ and related drugs. Molecular computations on CQ-resistance reversing agents have indeed determined that their common features are hydrophobicity and electronegativity (i.e. proton attraction) [55].

References
1. Gilles HM: Management of severe and complicated malaria, a practical handbook. World Health Organisation GENEVA 1991:56.
2. Warhurst DC and Thomas SC: Pharmacology of the malaria parasites. Biochem Pharmacol 1975, 24:2047-56.
3. Warhurst DC and Hockley DJ: The mode of action of chloroquine on Plasmodium berghei and P. cynomolgi. Nature 1967, 214:935-6.
4. Fitch CD: Plasmodium falciparum in owl monkeys: drug resistance and chloroquine binding capacity. Science 1970, 169:289-90.
5. Homwood CA, Warhurst DC, Peters W and Baggaley VC: Lysosomes, pH and the anti-malarial action of chloroquine. Nature 1972, 235:50-2.
6. Macumber PB and Sprinz H: Morphological effects of chloroquine on Plasmodium berghei in mice. Nature 1967, 214:917-9.
7. Chou AC, Chewi R and Fitch CD: Ferriprotoporphyrin IX fulfils the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry 1980, 19:1543-549.
8. Pagola S, Stephens PW, Bohle DS, Kosar AD and Madsen SK: The structure of malaria pigment beta-haematin. Nature 2000, 404:307-10.
9. Buttle GAH, Henry TA, Solomon W, Trevar AW and Gibbs EM: The action of the cinchona and certain other alkaloids in bird malaria. Biochemistry 1938, 24:47-58.
10. Taggart JV, Earle DP, Berliner RW, Zabrod CG, Welch WJ, Wise NB, Schroeder EF, London IM and Shannon JA: Studies on the chemo-therapy of the human malarias. III. The physiological distribution and antimalarial activity of the cinchona alkaloids. J Clin Invest 1948, 27(Suppl):80-86.
11. Trager W and Jensen JB: Human malaria parasites in continuous culture. Science 1976, 193:673-5.
12. Warhurst DC: The quinine-haematin interaction and its relationship to antimalarial activity. Biochem Pharmacol 1981, 30:3323-3327.
13. Wesche DL and Black J: A comparison of the antimarial activity of the cinchona alkaloids against P. falciparum in vitro. J Trop Med Hyg 1990, 93:153-159.

14. Karle JM, Olmeda R, Gerena L and Milhous WK: Plasmodium falciparum: Role of absolute stereochemistry in the antimarial activity of synthetic amino alcohol antimarial agents. Exp Parasitol 1993, 76:345-351.

15. Karle JM, Gerena L and Milhous WK: Stereochemical evaluation of the relative activities of the cinchona alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother 1992, 36:1538-1544.

16. Oleksyn BJ, Suszko-Purzycka A, Dive G and Lamotte-Brasseur J: Molecular properties of Cinchona alkaloids: a theoretical approach. J Pharm Sci 1992, 81:122-127.

17. Karle JM and Karle IL: Crystal structure of (-)-mefloquine hydrochloride reveals consistency of configuration with biological activity. Antimicrob Agents Chemother 2002, 46:1529-1534.

18. Van der Ward, Geoff JH and Hedges B: A high affinity binding of quinine to iron (III) porphyrin: novel formation of allosteric complexes from alcohols and amines. J Am Chem Soc 1984, 106:4945-4950.

19. Egan TJ, Ross DC and Adams PA: Quinoline anti-marial drugs inhibit spontaneous formation of beta-haematin (malaria pigment). FEBS Lett 1994, 352:16-21.

20. Kubinyi H: Lipophilicity and drug activity, in Progress in Drug Research 1979, 23:97-198. Birkhaurus (Basel).

21. Rekker RF: The hydrophobic fragmental constant. Its derivation and application, in The Hydrophobic Fragmental Constant 1977, 11-24. Elsevier (Amsterdam).

22. Hansch C and Leo A: Exploring QSAR: Fundamentals and Applications in Chemistry and Biology*, American Chemical Society, Washington, DC 1995, 1:120.

23. Scherrer RA and Howard SM: Use of distribution coefficients in quantitative structure-activity relationships. J Med Chem 1977, 20:53-58.

24. Grossi A, Uskokovic M, Gutzwiller J, Kreteti AU and Brener Z: Antimalarial activity of natural, racemic and unnatural dihydroquinine, dihydroquindoline and their various racemic analogs in mice infected with Plasmodium berghei. Experiencia 1971, 27:1100-1101.

25. Lej AO and Hansch C: Role of hydrophobic effects in mechanistic QSAR, in Perspectives in Drug Discovery and Design 1999, 1:7-25.

26. Brooks B, Majer C, Diiciency, DD, and Plata-Salaman C: The parametrization of lipophilicity and other structural properties in drug design. Advances in Drug Research 1987, 16:85.

27. Yaoon A, Cabantchik ZI and Ginsburg H: Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimarial drug chloroquine. EMBO J 1984, 3:2695-700.

28. Krosgstad DJ and Schlesinger PH: A perspective on antimarial action: effects of weak bases on Plasmodium falciparum. Biochem Pharmacol 1986, 35:547-552.

29. Hawley SR, Bray PG, Park BK and Ward SA: Anomadiquin accumulation in Plasmodium falciparum as a possible explanation for its superior antimarial activity over chloroquine. Mol Biochem Parasitol 1996, 80:15-25.

30. Avdeef A: pH-metric log P. 2: Refinement of partition coefficients and ionization constants of multiprotic substances. J Pharm Sci 1993, 82:183-190.

31. Chien YW, Lambert HJ and Karim A: Comparative binding of dioppyrmapide phosphate and quinidine sulfate to human plasma proteins. J Pharm Sci 1974, 63:1877-1879.

32. Takala-Novak K and Avdeef A: An interlaboratory study of log P determination by shake-flask and potentiometric methods. J Pharm Biomed Anal 1996, 14:405-13.

33. Parapini S, Basilico N, Pasini E, Egan TJ, Olliaro P, Taramelli D and Monti D: Standardization of the physicochemical parameters to assess in vitro the beta-haematin inhibitory activity of antimarial drugs. Exp Parasitol 2000, 96:249-56.

34. Allinger NL: Conformational Analysis 130. MM2. A Hydrocarbon Force Field Utilizing VI and V2 Torsional Terms. J Am Chem Soc 1977, 99:8127-8134. (MM+ is a HyperChem modification and extension of Normam Allinger’s Molecular Mechanics program MM2)

35. Stewart JP: Optimization of Parameters for Semi-empirical Methods. I. Method. J Comput Chem 1989, 10:209. PM3 is JJP Stew-
61. Warhurst DC, Craig JC and Adagu IS: Molecular basis of anionselectivity. J Biol Chem 2002, 277:49767-75.

62. Warhurst DC, Craig JC and Adagu IS: Lysosomes and drug resistance in malaria (Commentary). Lancet 2002, 360:1527-1529.

63. National Cancer Institute Database [http://dpc.donline.com/nihdps2/], accessed Nov. 18 2002

64. Moreau S, Perly B, Chachaty C and Deleuze C: The effect of intramolecular hydrogen bonding on partition coefficients of chloroquine and quinine in aqueous media. J Pharm Sci 1974, 63:876-880.

65. Tsai RS, Carrupt PA, Testa B, El Tayar N, Gruenewald G and Casey A: Influence of stereochemical factors on the partition coefficient of diastereomers. J Chem Research 1993:1901-1902.

66. Allen RI, Box KJ, Comer JEA, Peake C and Tam KY: Multiwavelength spectrophotometric determination of acid dissociation constants of ionizable drugs. J Pharm Biomed Anal 1998, 17:699-712.

67. Drezewicz C, Suszko-Purzycka A and Skolik J: Correlation between structure and basicity of Cinchona alkaloids. Polish J Chem 1993, 67:45-52.

68. Drezewicz C, Zalewski RI, Skolik J and Suszko-Purzycka A: Spectrophotometric determination of the second dissociation constant of Cinchona alkaloids. Polish J Chem 1993, 67:53-58.

69. Lepeit G: Die pH-abhängige Lipidlöslichkeit von Arzneistoffen, Pharmazie 1977, 32:289-291.

70. Hansch C and Anderson SM: The effect of intramolecular hydrophobic bonding on partition coefficients. J Org Chem 1967, 32:2833-2836.

71. Cassidy SL, Lynpany PA and Henry JA: Lipid solubility of a series of drugs. J Pharm Pharmac 1988, 40:130-132.

72. Unger SH and Chiang GH: Octanol-physiological buffer distribution coefficients of lipophilic amines and their correlation with biological activity. J Med Chem 1981, 24:262-270.

73. Warhurst DC, Steele JCF, Adagu IS, Craig JC and Cullander C: Hydroxylchloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 2003, 52:188-93.

74. Loyevsky M, John C, Zaloujny I and Gordeuk V: Aminothiol multideterminate chelators as antimalarials. Biochem Pharmacol 1997, 54:451-58.

75. Shanzer A, Libman J, Lyttton SD, Glickstein H and Cabantchik ZI: Peptidic siderophores act as antimalarial agents. Proc Natl Acad Sci U S A 1991, 88:6585-6589.

76. Kaschula CH, Egam TJ, Hunter R, Basilio N, Parapini S, Taramelli D, Pasini E and Monti D: Structure-activity relationships in 4-aminoquinoline antiparasitic photophore. The role of the group at the 7-position. J Med Chem 2002, 45:3531-3539.

77. Warhurst DC: Antimalarial schizonticides: why a permease is necessary. Parasitol Today 1986, 2:331-334.

78. Warhurst DC: Mechanism of chloroquine-resistance in malaria. Parasitol Today 1988, 4:211-213.

79. Bray PG, Howells RE, Ritchie GY and Ward SA: Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. A correlation of chloroquine sensitivity with energy-dependent drug accumulation. Biochem Pharmacol 1992, 44:1317-1324.